Mechanisms of resistance to Erbitux (anti–epidermal growth factor receptor) combination therapy in p...
Mechanisms of resistance to Erbitux (anti–epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
We previously demonstrated that pancreatic adenocarcinoma BxPC-3 xenografts display resistance to treatment with Erbitux, gemcitabine, and radiation, whereas MIA PaCa-2 xenografts are highly sensitive to the same therapy. Here, we elucidate in vitro mechanisms that may explain the observed differential response of epidermal growth factor receptor (...
Alternative Titles
Full title
Mechanisms of resistance to Erbitux (anti–epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_67161531
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_67161531
Other Identifiers
ISSN
1091-255X
E-ISSN
1873-4626
DOI
10.1016/j.gassur.2004.09.021
